SFOSF News and Press, Shanghai Fosun Pharmaceutical Co. Ltd. From 11/01/21

Shanghai Fosun Pharma announced a $628 million deal to acquire a 73% stake in vaccine company Chengdu Antejin Biotech. Shanghai Pharma subsidiary SPH SINE acquired greater China rights for two microbiome therapies from Korea's KoBioLabs in a $110 million deal. Suzhou Innovent and ...

Despite the recent selloff, shares of Revance Therapeutics are up 65% since I gave a very bullish recommendation 2 years ago. In that time, we have have seen an equity raise, acquisition of sales rights for RHA fillers from Teoxane, a convertible note offering and of course the COVID-...

Thomas Lohnes/Getty Images News The Chinese drug regulators have concluded a review of the COVID-19 vaccine co-developed by BioNTech (BNTX) and Fosun Pharma (SFOSF), reports Caixinglobal. The vaccine will be named Comirnaty, and it now heads to the review stage, Fosun, which is set to ma...

Just_Super/iStock via Getty Images In an unusual arrangement, Taiwan will receive an additional 10M doses of the BioNTech([[BNTX]] +4.6%)/Pfizer ([[PFE]] +0.9%) COVID-19 vaccine thanks to Taiwan Semiconductor Manufacturing Company ([[TSM]] +2.3%) and Hon Hai Precision Industry Company ([[HNHA...

Kite, a Gilead Company (GILD), announces that Fosun Kite Biotechnology Ltd., a joint venture between Kite and Shanghai Fosun Pharmaceutical (SFOSF), has received approval in China for axicabtagene ciloleucel for the treatment of adult patients with relapsed or refractory large B-cell lymphoma...

Messenger RNA-based technology that is highly effective in preventing Covid-19 can also be used for treatment of other diseases. High efficacy rates in preventing Covid-19 spark rush by Chinese companies into mRNA vaccines and treatments. At least one Chinese-made mRNA Covid vacci...

Shanghai Fosun Pharmaceutical (SFOSF) and BioNTech (BNTX) are setting up a joint venture ((JV)) in China with the capacity to manufacture up to 1B doses of the shot to protect against COVID-19. In a stock filing, the SFOSF said night that the companies will invest up to $100M each to set...

CANbridge will make a $10 million upfront payment for the two Fabry and Pompe candidates. Guangzhou Link Health Pharma and Australia's George Clinical plan to form a China clinical CRO JV that will conduct trials for Link Health's in-licensed portfolio. Discovered by CStone's part...

Zai Lab raised a staggering $750 million in a private placement of its dual US/Hong Kong-listed stock. Shanghai Junshi Bio completed its $50 million investment into its US partner, Coherus BioSciences. Tianjin CanSino Biologics will start a clinical trial of an inhaled COVID-19 va...

The head of the American Chamber of Commerce in Shanghai  tells Bloomberg that that Chinese government is set to approve the BioNTech (BNTX) COVID-19 vaccine in June.The comments from Ker Gibbs echo a report last week in The Wall Street Journal.Shanghai Fosun Pharmaceutical (SFOSF) will ...